

Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Authorised

- Dexamethasone sodium phosphate

Product identification

Medicine name:

Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Active substance:

Dexamethasone sodium phosphate

Target species:

Horse

Cattle

Dog

Cat

Pig

Route of administration:

Intraarticular use

Intramuscular use

Intravenous use

Product details

Active substance and strength:

Dexamethasone sodium phosphate

2.63 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intraarticular use:

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

Intramuscular use:

-

Cattle

- Meat and offal. 8 day
- Milk. 72 hour

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

-

Pig

- Meat and offal. 2 day

Intravenous use:

-

Horse

- Meat and offal. 8 day
- Milk. no withdrawal period

Not authorised for use in horses producing milk for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QH02AB02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Latvia

Available in:

Latvia

Package description:

Available only in Latvian

Available only in Latvian

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dopharma Research B.V.

Marketing authorisation date:

14/08/2012

Manufacturing sites for batch release:

Dopharma B.V.

Responsible authority:

Food And Veterinary Service

Authorisation number:

V/DCP/12/0053

Date of authorisation status change:

14/08/2012

Reference member state:

Ireland

Procedure number:

IE/V/0293/001

Concerned member states:

Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland France
Germany Greece Hungary Iceland Italy Latvia Lithuania Netherlands
Norway Poland Romania Slovakia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet